Ticrynafen-induced phenytoin toxicity: an interaction 1 Saeed Ahmad MD MRCP 2 Fairmont General Hospital Fairmont. West Virginia 26554, USA Ticrynafen (known as tienilic acid in Europe), a newly synthesized agent. appeared to be a useful new antihypertensive drug because of its unique combination of diuretic, antihypertensive, and hypouricaemic effects. This agent has not proved to be an unmixed blessing. Recently. the manufacturers withdrew the drug from the market because five patients died while they were on ticrynafen therapy.
In an editorial. Barclay (1980) commented that these deaths may, of course. have been unrelated to the drug. and a careful re-evaluation of ticrynafen may lead to its reintroduction. Physicians should. however be thoroughly familiar with the adverse effects of this agent should it be reintroduced. Recognition of drugdrug interactions is of vital importance as it may prevent serious complications and hence result in better clinical judgment. Weber & Fishman (1979) described a patient taking both ticrynafen and phenytoin who showed signs of phenytoin toxicity. Ticrynafen was discontinued and gradual resolution of the symptoms took place over the ensuing weeks.
A case is now reported of acute cerebellar syndrome due to ticrynafen-induced phenytoin toxicity, which completely resolved on withdrawal of ticrynafen.
Case report
In 1972a 37-year-old white man was diagnosed as having grand mal epilepsy of undetermined aetiology. He was started on phenobarbitone 15 mg three times a day. This proved insufficient, and in 1973 phenytoin 300 mg daily was added to his regime. His seizure disorder has been well under control, with serum phenytoin levels in 'Accepted 18 November 1980 2Correspondence to: 1489 Locust Avenue, Fairmont, West Virginia 26554, USA 0141-0768/81/020162-02/$01.00/0 therapeutic range. In early September 1979, ticrynafen 250 mg a day was instituted to control his blood pressure and hyperuricaemia. After three weeks of treatment with ticrynafen, he began to experience tremors in the right arm, severe aches and pains in both thighs and arms, severe headaches, extreme restlessness, paraesthesia of the lower extremities, unsteadiness, syncopal attacks, confusion and depression. His wife noticed that he was apathetic and would 'sob like a baby.'
By the fourth week of ticrynafen treatment, the patient also had slurred speech, marked difficulty in walking and profuse mental confusion. Clinical examination revealed a tearful, and depressed young man with nystagmus, cerebellar ataxia and dysarthria. A presumptive diagnosis of phenytoin toxicity due to an interaction was made and hence ticrynafen was stopped immediately. His wife had already decreased the dose of phenytoin to 100mg daily on the third week of ticrynafen therapy when he started having 'problems'. Complete blood count and SMA-12 profile did not reveal any abnormality. The serum phenytoin level was 30.2 j.tg/ml (one week after phenytoin 100 mg daily).
Marked improvement was noted over the next three weeks when the serum phenytoin level was noted to be 10.2 j.tg/ml. Complete resolution of all the symptoms took place over the next three weeks. I suggest that this patient had central nervous system toxicity related to phenytoin/ticrynafen interaction.
Discussion
Ticrynafen may decrease the excretion of penicillins and aspirin (Medical Letters 0/1 Drugs and Therapeutics 1979). Anticoagulant potentiation and haemorrhage have been documented when ticrynafen was used concurrently with warfarin (Slattery & Levy 1979) . One patient died shortly after hospitalization, and autopsy disclosed a large retroperitoneal haematoma (McLain et al. 1980) . Acute renal failure, renal stones and hepatotoxicity are well known adverse reactions associated with ticrynafen use (Sawa et al. 1980) . I believe the present case is the first documented example of the toxic interaction between phenytoin and ticrynafen. Serum phenytoin levels prior to ticrynafen ranged between 5-10 j.tg/ml, and steady state serum phenytoin levels have been in the same range on 300mg/day.
In vitro studies with ticrynafen have shown competition from albumin binding sites. Caution should be exercised when this agent is used concurrently with other drugs, like phenytoin, tolbutamide and warfarin, that are weakly protein bound. Ticrynafen is very highly protein bound, therefore it displaces phenytoin which is weakly © 1981 The Royal Society of Medicine Journal of the Royal Society of Medicine Volume 74 February 1981 163 bound to blood proteins (product information, Smith Kline & French 1979). Ticrynafen may inhibit the parahydroxylation of phenytoin in the liver, thereby increasing the serum levels of phenytoin to a point where signs of phenytoin intoxication occur. The interrelationship of these two drugs is rather complex. Therefore a drug may be exposed to the effects of interaction at more than one site and more than one mechanism. Anticonvulsant drugs like the anticoagulants, antihypertensives and antidiabetics are used within a rigid sphere of patient stabilization. Drug-drug interactions therefore exert a special hazard in such cases. Whatever the mechanism, the toxic effects from therapy with phenytoin are greatly increased among patients concurrently receiving ticrynafen therapy. Schedules of dosage for phenytoin and warfarin should be appropriately adjusted to compensate for this clinically important interaction of drugs.
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The case is described of a three-year-old girl Who survived a generalized BCG infection. Most reported cases have died despite antituberculous therapy (Pedersen et al. 1978) . Our patient was treated with antituberculous drugs, but only improved rapidly when she was given clofazimine, a phenazine congener. Clofazimine has been used successfully in lepromatous leprosy. Little is known about the mode of action of this drug, but it appears to exert an anti-inflammatory effect When given in adequate dosage and prevents the development or erythema nodosum (Browne 1967 
Case report.
KA was a normal full-term delivery. She had three attacks of catarrh-like fever in the first few months of life. The Mantoux test was negative at 6 months and she was given a BCG vaccination in France. The Mantoux test was repeated at one year but was still negative and she was given further BCG. The vaccination site failed to heal and she became unwell with generalized lymphadenopathy.
BCG'osis was diagnosed and she was given a 3month course of ethambutol and isoniazid, following which she improved and the lymphadenopathy regressed. However, three months after discontinuing the drugs she relapsed. A large lymph node containing numerous noncaseating granulomata ( Figure I) was removed from the left axilla. The operation site failed to heal and she developed a chronic discharging sinus (Figure 2 ). She also developed severe generalized eczema which became prone to secondary bacterial infection.
She was first seen at Northwick Park Hospital at 26 months of age. BCG'osis was confirmed by finding numerous acid fast bacilli in a swab taken 
